Full text is available at the source.
Why does GLP ‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP ‐1 agonist alone in obese adults without type 2 diabetes?
Why combining GLP-1 with GIP and/or GCG agonists causes more weight loss than GLP-1 alone in obese adults without diabetes
AI simplified
Abstract
Liraglutide and semaglutide, both approved for long-term weight management, significantly reduce food intake and delay gastric emptying.
- Unimolecular polypharmacology represents an advance in obesity treatment by using single molecules to target multiple pathways.
- Tirzepatide, a dual agonist, activates both GLP-1 and GIP receptors, showing enhanced weight loss potency compared to traditional GLP-1 mono agonists.
- Preliminary data indicate that GLP-1/glucagon dual agonists and GLP-1/GIP/glucagon triple agonists may provide better weight loss results than GLP-1 mono agonists.
- Understanding the mechanisms of these unimolecular multitargeting agents could inform future clinical applications and drug development for obesity.
AI simplified